National Cancer Center introduces new treatment strategy by applying protein genome research to ‘biliary tract cancer’

Park Sangjae (Clinical Professor, Pancreatic Hepatobiliary Cancer Centre), Department of Oncology, National Cancer Center

A research team at the National Cancer Center (President Seo Hong-gwan) has applied protein genome research to bile duct cancer in the liver, which is an incurable cancer, to identify cancer characteristics and introduce a new treatment strategy that is subdivided .

Protein genome research is a research method that can overcome the limitations of precision medicine, which has only responded to some cancer patients, by integrating and analyzing data such as genome, transcriptome, proteome, and protein phosphorylation, taking a leap forward from the current genome and studies transcribe. is popularized as

Sang-Jae Park (Clinical Professor, Hepatobiliary Pancreatic Cancer Center), Department of Oncology, National Cancer Center, Woo Sang-Myung (Clinical Professor, Hepatobiliary Pancreatic Cancer Center), Department of Tumor Immunology, Yun-Hee Kim, Department of Molecular Imaging, Prof Soo-Young Cho, Department of Molecular Life Science, Hanyang University, Korea Foundation of Basic Science (President) Shin Hyung-sik Kim and Dr. Hwang Hee-yeon’s research team applied protein genome research to bile duct cancer of the liver, an incurable cancer, to analyze the effects genetic mutations and open up the possibility of customized treatment tailored to each patient’s characteristics.

Intrahepatic cholangiocarcinoma is a cancer of the biliary tract, the path through which bile is transported within the liver. Accordingly, the research team conducted a protein genome study on 102 intrahepatic bile duct cancer tumor tissues and verified the treatment method through a tumor organoid model.

In particular, the research team identified three subtypes: ▲stem-like ▲poor immunogenic ▲metabolism. In the stem cell-like subtype, aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitor reacted with nab-paclitaxel, confirming the result of an increased inhibitory effect. In addition, abnormal oncomometabolite expression in both the stem cell-like subtype and the metabolite subtype was verified to be associated with survival time. In particular, in the case of the low immunogenicity subtype, T cell tumor infiltration was confirmed to be low compared to other subtypes. This integrated multi-omics analysis reproduced all three types and demonstrated intrahepatic cholangiocarcinoma tumor heterogeneity.

Dr. Kim Jin-young from the Korea Foundation for Basic Science said, “This is the first time in the field of proteomics to report a tissue sample from a patient with bile duct cancer in the liver through a proteome study.” it will be used for artificial intelligence and machine learning research and development for bio-big data analysis.”

Professor Woo Sang-myung from the National Cancer Center said, “This large-scale protein genome analysis provides information beyond genome analysis and is significant as it allows us to distinguish between functional effects genetic mutations.” “We will be able to deliver a tailored, tailored treatment for patients by classifying them according to the treatment and develop reasonable treatment strategies accordingly.”

This research is a cancer protein genomic research project of the National Cancer Center, a multi-omics big data project of the Korea Foundation for Basic Science, and a non-/invasive human-derived material discovery and self-analysis technology development project low the National Science and Technology Research Council The results of the research were published online in the latest issue of Gastroenterology (IF 33.883), the official academic journal of the American Gastroenterology, which is famous throughout the world.

* ALDH1A1: A type of aldehyde dehydrogenase (ALDH) that includes a family of enzymes that play an important role in the oxidation of various cytotoxic heterologous and biogenic aldehydes.

* Nab-paclitaxel: Paclitaxel-nanoparticle bound with albumin Paclitaxel is a taxane-based anticancer agent and is classified as an antimicrotubule agent and plant alkaloids. This drug stops the spread of cancer cells by interfering with the process of separating microtubules, which are mechanisms for division and self-replication during cell division, and this anticancer drug is used for cancers of the breast, lung, the pancreas and the ovary.

* Tumor metabolites: Refers to metabolites that are significantly increased in tumors compared to normal cells.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.